Sugi Predict

Sugi Predict / Compounds / SCHEMBL133581

SCHEMBL133581

SCHEMBL133581

CC(=O)OC[C@H]1O[C@H](O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.60
▸ THRB P10828 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ TSHR P16473 1/20 0.58
▸ NR3C1 P04150 1/20 0.58
▸ FYN P06241 1/20 0.58
▸ ADRA2A P08913 1/20 0.58
▸ ADORA3 P0DMS8 1/20 0.58
▸ ADRA2B P18089 1/20 0.58
▸ DRD4 P21917 1/20 0.58
▸ DRD3 P35462 1/20 0.58
▸ CA2 P00918 12/20 0.57
▸ CA12 O43570 11/20 0.57
▸ CA1 P00915 11/20 0.57
▸ CA9 Q16790 6/20 0.57
▸ PKM P14618 1/20 0.52
▸ PTPN1 P18031 1/20 0.52
▸ CA4 P22748 7/20 0.50
▸ CA5A P35218 7/20 0.50
▸ CA7 P43166 7/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582590 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL133580 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL18652541 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL13465295 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL3188307 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL18880355 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL12569416 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL1140728 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL22766232 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1
SCHEMBL17119468 1.00 CYP2D6 (0.60) CYP2D6THRBHSD17B10TSHRNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115636856-A beta-Gal response-based ultraviolet-visible multifunctional fluorescent linker, and preparation method and application thereof 西安交通大学 2023-01-24 — — CN claimed
CN-115521350-A Near-infrared one-zone multifunctional fluorescent linker based on beta-lactase response, preparation method and application 西安交通大学 2022-12-27 — — CN claimed
US-10640526-B2 Method of preparation of 6-azido-2,4-diacetamido-2,4,6-trideoxy-D-mannose CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-05 — — US claimed
EP-3377508-A1 METHOD OF PREPARATION OF 6-AZIDO-2,4-DIACETAMIDO-2,4,6-TRIDEOXY-D-MANNOSE Centre National De La Recherche Scientifique (FR) 2018-09-26 — — EP claimed
EP-3170832-A1 METHOD OF PREPARATION OF 6-AZIDO-2,4-DIACETAMIDO-2,4,6-TRIDEOXY-D-MANNOSE Centre National De La Recherche Scientifique (FR) 2017-05-24 — — EP claimed
EP-0511917-B1 Glycosylated prodrugs, process for their preparation and uses thereof HOECHST SA LAB (FR) 1996-10-23 — — EP claimed
WO-1992019639-A1 GLYCOSYLATED PRODRUGS, METHOD OF PREPARATION AND USE LABORATOIRES HOECHST (FR) 1992-11-12 — — WO claimed
EP-0511917-A1 Glycosylated prodrugs, process for their preparation and uses thereof LABORATOIRES HOECHST S.A. (FR) 1992-11-04 — — EP claimed
JP-58072599-A — — None — — JP disclosed
US-20240299554-A1 PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS PHARMACYTICS B.V. (NL) 2024-09-12 — — US disclosed
CN-114920788-B Preparation of human milk trisaccharide galactosyl lactose 天津科技大学 2024-07-30 — — CN disclosed
EP-4359419-A1 PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS Pharmacytics B.V. (NL) 2024-05-01 — — EP disclosed
US-20230321284-A1 COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE (JP) 2023-10-12 — — US disclosed
EP-4148059-A1 COMPOUND, CONTRAST MEDIUM, AND METHOD FOR PRODUCING COMPOUND St. Marianna University School of Medicine (JP) 2023-03-15 — — EP disclosed
EP-0511917-A1 Glycosylated prodrugs, process for their preparation and uses thereof LABORATOIRES HOECHST S.A. (FR) 1992-11-04 — — EP disclosed
WO-1992009612-A1 PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-06-11 — — WO disclosed
US-5095123-A Phosphorylation E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-03-10 — — US disclosed
US-4855417-A Anomeric deacetylation YEDA RESEARCH AND DEVELOPMENT COMPANY LTD (IL) 1989-08-08 — — US disclosed
EP-0226183-A2 Anomeric deacetylation BAR-ILAN UNIVERSITY (IL) 1987-06-24 — — EP disclosed
JP-S5872599-A CONJUGATED GLYCOSIDE DERIVATIVE KANTO ISHI PHARMA CO LTD 1983-04-30 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299554-A1 PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS SI, SULT1E1, SULT1A1 CYP2D6 19/4885THRB 2467/4885HSD17B10 1224/4885
US-10640526-B2 Method of preparation of 6-azido-2,4-diacetamido-2,4,6-trideoxy-D-mannose ST6GAL1, B4GALT1, GALNT6 CYP2D6 986/4885THRB 268/4885HSD17B10 4875/4885
US-20230321284-A1 COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND RXFP1, AVPR2, RXFP3 CYP2D6 3235/4885THRB 3616/4885HSD17B10 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback